Airway diseases
Guidelines session
Severe asthma guidelines: update 2019
Clinical
ERS/ATS guidelines
Aims : to review the role of biomarkers in treatment planning for severe asthma; to discuss the roles of new anti-type monoclonal antibodies in TH2-high asthma; to explore the treatment of non-eosinophilic asthma with specific reference to long-acting muscarinic agents and macrolides.
Link to guidelines
Target audience :
Allergist, Clinical researcher, Critical/Intensive care physician, General practitioner, Nurse, Paediatrician, Pathologist, Patient, Physiologist, Scientist (basic, translational), Student, Trainee, Adult pulmonologist/Clinician
Methods :
Cell and molecular biology, Physiology, Pulmonary function testing, Respiratory intensive care
08:30
Clinical approach to very severe asthma and changes from the previous ERS-ATS task force
J. Cardet(Tampa, United States)
COI
-
Description
1
214
09:00
The role of biomarkers in the management of severe asthma
K. Chung(London, United Kingdom)
COI
-
Description
2
215
09:30
TH2-high asthma: a practical approach with cases and interactive questions
P. Nair(Hamilton (ON), Canada)
COI
-
Description
3
216
10:00
Non-eosinophilic asthma: a practical approach with cases and interactive questions
F. Schleich(Liège, Belgium)
COI
-
Description
4
217
. . .
